Navigation Links
OTC sale for Xenical; Diet Drug; gets FDA approval

Prescription diet drug Xenical manufactured by GlaxoSmithkline got a nod for OTC sale from FDA.It received an "approvable" letter from the Food// and Drug Administration so that it can be marketed once the company addresses additional questions from regulators. An estimated arrival time for the sale is early next year.

It would become the first F.D.A.-approved weight-loss product sold without a doctor's prescription. The diet drug has been christened Alli.

A federal advisory panel voted 11 to 3 in January that the drug, which works by blocking fat absorption, could be sold without a prescription.

Although Xenical has been available as a prescription drug since 1999, it never got the star status partly because about half of the people who use it have episodes of diarrhoea, oily stools and flatulence because of fat that is excreted from the body rather than absorbed.

Clinical studies of the lower-dose over-the-counter version have shown that people using the drug lose more than their counterparts on similar diets who do not take the medication — an average of about five to six additional pounds more over six months. About 18 percent lose 10 percent or more of their initial body weight.

If it wins final approval, it would be the only FDA-endorsed weight-loss drug available without a prescription. But some experts express concern about people regaining weight after they stop using the drug, as well as whether people will be able to tell if it is safe for them without a doctor's advice. The drug can also lead to hepatitis, gallstones and kidney stones, although the exact cause is not clear.

But Gbola Amusa, an analyst in London for Sanford C. Bernstein & Company, said, "I'm assuming that the F.D.A. is addressing some things related to how they can ensure that this drug is not used inappropriately”.

So the diet pill Xenical would soon be seen in shops.


'"/>




Page: 1

Related medicine news :

1. Ranbaxy gets US FDA approval for Lisinopril
2. Aurobindo gets U.S. FDA approval for Cephalexin
3. Cadila gets US FDA approval for Promethazine tablets
4. Anti-obesity drugs for FDA approval
5. Grand FDA nod and approval for drug for heart transplant patients
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/25/2017)... ... September 25, 2017 , ... ... technology-enabled services supporting clinical research, today announces that 30 of its domain ... the drug development lifecycle at upcoming industry conferences and webinars. Drawing on ...
(Date:9/25/2017)... ... September 25, 2017 , ... Earlypicker is expanding its offerings ... shop for the hottest Korean cosmetics and fashion trends sweeping the nation. The decision ... already well-known for the great offerings that allow Koreans everywhere to look their best ...
(Date:9/25/2017)... , ... September 25, 2017 , ... “The Majestic Unicorn”: ... the great flood. “The Majestic Unicorn” is the creation of published author, Dayna Chantel, ... small, came from far and wide to march aboard the cypress ark-vessel. Male and ...
(Date:9/25/2017)... Philadelphia, PA (PRWEB) , ... September 25, 2017 , ... Emerald Ash Borers ... pest's destruction can be seen throughout the Philadelphia region. A video by Rob Nagy, ... is lined with Ash trees. While several are dead or showing signs of decline ...
(Date:9/24/2017)... ... ... Throughout the United States and the world, clinicians take a simple but ... providers work to give the best care possible to patients and communities, while seeking ... are threatening to tie our hands in carrying out that oath. The Graham-Cassidy legislation ...
Breaking Medicine News(10 mins):
(Date:9/9/2017)... 2017 ... coming to Washington DC ... Tuesday, September 12 th – Monday, September 18 th .The Brain ... MRI brain scans to the public.Where:  BTF,s Mobile ... 501 K Street NW, Washington, D.C.What:BTF brings its nationwide initiative, the Road ...
(Date:9/9/2017)... 9, 2017  Eli Lilly and Company (NYSE: ... endpoint data for lasmiditan, an investigational, oral, first-in-class molecule ... significant improvements compared to placebo in the Phase 3 ... the 18th Congress of the International Headache Society (IHC) ... data presented today demonstrate lasmiditan,s potential to reduce pain ...
(Date:9/7/2017)... -- For nearly two decades, New Life Agency has been committed to providing ... New Life Agency announces a powerful three-way partnership designed to deliver substantial ... ... http://www.schrafts2.com/ ... http://pharmacarecard.com/ (PRNewsfoto/PharmaCareCard) ...
Breaking Medicine Technology: